Search research articles
Contact Us
Filters
Showing results (31-40 of 69) with videos related to
Page
of 7
Sort By:
Investigational New Drugs
|
August 22, 2014
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma
Nizar M Tannir, Andres Forero-Torres, Radhakrishnan Ramchandren, et al.
Leukemia & Lymphoma
|
March 3, 2015
Management of adverse events associated with idelalisib treatment: expert panel opinion
Steven E Coutré, Jacqueline C Barrientos, Jennifer R Brown, et al.
Blood
|
February 8, 2017
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Ariela Noy, Sven de Vos, Catherine Thieblemont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2006
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I Fisher, Steven H Bernstein, Brad S Kahl, et al.
Hemasphere
|
November 15, 2019
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Steven E Coutre, Ian W Flinn, Sven de Vos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 7, 2012
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma
Andres Forero-Torres, Sven de Vos, Brad L Pohlman, et al.
Nature Medicine
|
March 22, 2022
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
Sattva S Neelapu, Michael Dickinson, Javier Munoz, et al.
Blood
|
December 8, 2009
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W Friedberg, Jeff Sharman, John Sweetenham, et al.
British Journal of Haematology
|
March 18, 2020
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma
Nathan H Fowler, Loretta Nastoupil, Sven De Vos, et al.
Blood Advances
|
January 4, 2018
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
Sven de Vos, Nina D Wagner-Johnston, Steven E Coutre, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 69) with videos related to
Sort By:
Page
of 7
Investigational New Drugs
|
August 22, 2014
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma
Nizar M Tannir, Andres Forero-Torres, Radhakrishnan Ramchandren, et al.
Leukemia & Lymphoma
|
March 3, 2015
Management of adverse events associated with idelalisib treatment: expert panel opinion
Steven E Coutré, Jacqueline C Barrientos, Jennifer R Brown, et al.
Blood
|
February 8, 2017
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Ariela Noy, Sven de Vos, Catherine Thieblemont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2006
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I Fisher, Steven H Bernstein, Brad S Kahl, et al.
Hemasphere
|
November 15, 2019
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Steven E Coutre, Ian W Flinn, Sven de Vos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 7, 2012
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma
Andres Forero-Torres, Sven de Vos, Brad L Pohlman, et al.
Nature Medicine
|
March 22, 2022
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
Sattva S Neelapu, Michael Dickinson, Javier Munoz, et al.
Blood
|
December 8, 2009
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W Friedberg, Jeff Sharman, John Sweetenham, et al.
British Journal of Haematology
|
March 18, 2020
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma
Nathan H Fowler, Loretta Nastoupil, Sven De Vos, et al.
Blood Advances
|
January 4, 2018
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
Sven de Vos, Nina D Wagner-Johnston, Steven E Coutre, et al.
Page
of 7